These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22676879)

  • 21. Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere.
    Vickerman P; Martin N; Hickman M
    Drug Alcohol Depend; 2011 Jan; 113(2-3):83-5; discussion 86-7. PubMed ID: 20832198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments.
    Scott N; McBryde E; Vickerman P; Martin NK; Stone J; Drummer H; Hellard M
    BMC Med; 2015 Aug; 13():198. PubMed ID: 26289050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.
    Arain A; Robaeys G
    World J Gastroenterol; 2014 Sep; 20(36):12722-33. PubMed ID: 25278674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
    Lima VD; Rozada I; Grebely J; Hull M; Lourenco L; Nosyk B; Krajden M; Yoshida E; Wood E; Montaner JS
    PLoS One; 2015; 10(12):e0143836. PubMed ID: 26633652
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C transmission and treatment in contact networks of people who inject drugs.
    Rolls DA; Sacks-Davis R; Jenkinson R; McBryde E; Pattison P; Robins G; Hellard M
    PLoS One; 2013; 8(11):e78286. PubMed ID: 24223787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.
    Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011644. PubMed ID: 28285495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago.
    Echevarria D; Gutfraind A; Boodram B; Major M; Del Valle S; Cotler SJ; Dahari H
    PLoS One; 2015; 10(8):e0135901. PubMed ID: 26295805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?
    Stone J; Martin NK; Hickman M; Hellard M; Scott N; McBryde E; Drummer H; Vickerman P
    PLoS One; 2016; 11(5):e0156213. PubMed ID: 27224423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.
    Stone J; Martin NK; Hickman M; Hutchinson SJ; Aspinall E; Taylor A; Munro A; Dunleavy K; Peters E; Bramley P; Hayes PC; Goldberg DJ; Vickerman P
    Addiction; 2017 Jul; 112(7):1302-1314. PubMed ID: 28257600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data.
    Palmateer NE; McAuley A; Dillon JF; McDonald S; Yeung A; Smith S; Barclay S; Hayes P; Shepherd SJ; Gunson RN; Goldberg DJ; Hickman M; Hutchinson SJ
    Addiction; 2021 Oct; 116(10):2893-2907. PubMed ID: 33651446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
    Hartwell D; Jones J; Baxter L; Shepherd J
    Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
    Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
    J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C transmission and treatment as prevention - The role of the injecting network.
    Hellard M; McBryde E; Sacks Davis R; Rolls DA; Higgs P; Aitken C; Thompson A; Doyle J; Pattison P; Robins G
    Int J Drug Policy; 2015 Oct; 26(10):958-62. PubMed ID: 26072105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study.
    Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore GJ; Grebely J
    Clin Infect Dis; 2021 Jul; 73(1):e69-e78. PubMed ID: 32421194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Addicts with chronic hepatitis C: difficult to reach, manage or treat?
    Zanini B; Benini F; Pigozzi MG; Furba P; Giacò E; Cinquegrana A; Fasoli M; Lanzini A
    World J Gastroenterol; 2013 Nov; 19(44):8011-9. PubMed ID: 24307794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study.
    Cunningham EB; Hajarizadeh B; Dalgard O; Amin J; Hellard M; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Bruneau J; Midgard H; Bourgeois S; Thurnheer MC; Dore GJ; Grebely J;
    BMC Infect Dis; 2017 Jun; 17(1):420. PubMed ID: 28610605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users.
    Gigi E; Sinakos E; Sykja A; Androulakis G; Tanis C; Stayridou V; Tsirogianni E; Zouridakis K; Bellou AL; Orfanou E; Raptopoulou-Gigi M
    J Addict Med; 2013; 7(1):52-7. PubMed ID: 23340710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies.
    Iversen J; Wand H; McManus H; Dore GJ; Maher L
    Addiction; 2023 May; 118(5):901-911. PubMed ID: 36524842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study.
    Nguyen OK; Dore GJ; Kaldor JM; Hellard ME;
    Int J Drug Policy; 2007 Oct; 18(5):447-51. PubMed ID: 17854736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.
    Martin NK; Hickman M; Hutchinson SJ; Goldberg DJ; Vickerman P
    Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S39-45. PubMed ID: 23884064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.